Clinical trial

Brain Microglial Activation in the Early Stage of the Parkinson's Disease: a Predictive Biomarker of the Evolution?

Name
RC17_0012
Description
Phase II, Open-labeled, Prospective, Multi-center study of assessing the link between microglial activation and dopaminergic denervation kinetics in the early stage of Parkinson disease, by using the imaging of \[18F\]DPA-714 a new ligand of Translocator Protein-18 kDa (TSPO) by Positron Emission Tomography (PET).
Trial arms
Trial start
2018-04-16
Estimated PCD
2024-05-06
Trial end
2024-05-06
Status
Active (not recruiting)
Phase
Early phase I
Treatment
[18F]DPA-714 PET scan
One PET scan using \[18F\]DPA-714 is done at M2 between two \[123I\]FP-CIT scan (DaTscan) done at M1 and M23. Neuropsychological assessment is done at M0, M18 and M24
Size
31
Primary endpoint
Coefficient of correlation between level of microglial striatal activation and the And the dopaminergic denervation kinetics
24 months
Eligibility criteria
Inclusion Criteria: * Patients having a Parkinson's disease diagnosed according to the criteria UKPDSBB. * Diagnosis done less than three years before the date the inclusion. * Patient Age at diagnosis : between 40 and 65 years. * Absence of clinical arguments for an associated neurovascular pathology. * Written consent obtained. * HAB polymorphism in the genotyping of TSPO gene. * Brain MRI without following abnormalities: cortical or sub-cortical atrophy or hippocampal atrophy (Scheltens score ≥2), vascular encephalopathy (Fazekas score \> 2, \> 10 microbleed) or showing signs in favour of atypical parkinson syndrome. Exclusion Criteria: * Pregnant woman * Minor * Adult protected by the law * Contraindication to PET-scan * Contraindication to brain MRI * History of inflammatory or dysimmune chronic disease * History of psychiatric disease or drug addiction * History of cognitive disorders (MMS\<26) * Hypersensibility to iodine derivates or one of these components * Long-term Treatments which can interfere in neuroinflammation process * Treatments / substances susceptible to interfere with the 18F-DPA-714 * TSPO gene Polymorphisms rs6971 corresponding to groups of affinity of low affinity (LAB=Low Affinity Binder) or moderated MAB = Mixed Affinity Binder) * Modification of diagnosis of Parkinson disease during follow-up, in particular towards an atypical parkinson-like syndrome
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 31, 'type': 'ACTUAL'}}
Updated at
2024-04-25

1 organization

1 product

1 indication

Product
DPA-714